Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin

• Published in: Neuro-oncology (Charlottesville, Va.) Va.), 2017-02, Vol.19 (2), p.197-207
• Main Authors: Kim, Eui Hyun, Lee, Ji-Hyun, Oh, Yoonjee, Koh, Ilkyoo, Shim, Jin-Kyoung, Park, Junseong, Choi, Junjeong, Yun, Mijin, Jeon, Jeong Yong, Huh, Yong Min, Chang, Jong Hee, Kim, Sun Ho, Kim, Kyung-Sup, Cheong, Jae-Ho, Kim, Pilnam, Kang, Seok-Gu
• Format: Article
• Language: English
• Subjects: Animals; Antimetabolites - pharmacology; Apoptosis - drug effects; Basic and Translational Investigations; Brain Neoplasms - drug therapy; Brain Neoplasms - metabolism; Brain Neoplasms - pathology; Cell Proliferation - drug effects; Deoxyglucose - pharmacology; Drug Synergism; Drug Therapy, Combination; Energy Metabolism - drug effects; Glioblastoma - drug therapy; Glioblastoma - metabolism; Glioblastoma - pathology; Glycolysis - drug effects; Humans; Hypoglycemic Agents - pharmacology; Metformin - pharmacology; Mice; Mice, Nude; Oxidative Phosphorylation - drug effects; Tumor Cells, Cultured; Xenograft Model Antitumor Assays
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/now174

Deprivation of tumor bioenergetics by inhibition of multiple energy pathways has been suggested as an effective therapeutic approach for various human tumors. However, this idea has not been evaluated in glioblastoma (GBM). We hypothesized that dual inhibition of glycolysis and oxidative phosphorylation could effectively suppress GBM tumorspheres (TS). Effects of 2-deoxyglucose (2DG) and metformin, alone and in combination, on GBM-TS were evaluated. Viability, cellular energy metabolism status, stemness, invasive properties, and GBM-TS transcriptomes were examined. In vivo efficacy was tested in a mouse orthotopic xenograft model. GBM-TS viability was decreased by the combination of 2DG and metformin. ATP assay and PET showed that cellular energy metabolism was also decreased by this combination. Sphere formation, expression of stemness-related proteins, and invasive capacity of GBM-TS were also significantly suppressed by combined treatment with 2DG and metformin. A transcriptome analysis showed that the expression levels of stemness- and epithelial mesenchymal transition-related genes were also significantly downregulated by combination of 2DG and metformin. Combination treatment also prolonged survival of tumor-bearing mice and decreased invasiveness of GBM-TS. The combination of 2DG and metformin effectively decreased the stemness and invasive properties of GBM-TS and showed a potential survival benefit in a mouse orthotopic xenograft model. Our findings suggest that targeting TS-forming cells by this dual inhibition of cellular bioenergetics warrants expedited clinical evaluation for the treatment of GBM.